Leerink Partners Reaffirms Market Perform Rating for Enhabit (NYSE:EHAB)

Enhabit (NYSE:EHAB)‘s stock had its “market perform” rating reiterated by stock analysts at Leerink Partners in a research report issued on Tuesday,Benzinga reports. They presently have a $8.00 target price on the stock, down from their previous target price of $8.50. Leerink Partners’ target price would suggest a potential upside of 7.24% from the company’s current price.

Enhabit Trading Up 2.6 %

Shares of EHAB opened at $7.46 on Tuesday. The firm has a market capitalization of $375.12 million, a P/E ratio of -3.22 and a beta of 1.84. The company has a current ratio of 1.46, a quick ratio of 1.46 and a debt-to-equity ratio of 0.85. The firm has a 50-day moving average price of $7.52 and a 200 day moving average price of $8.42. Enhabit has a 12-month low of $6.85 and a 12-month high of $11.74.

Enhabit (NYSE:EHAB) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.01). The company had revenue of $253.60 million during the quarter, compared to analyst estimates of $261.69 million. Enhabit had a positive return on equity of 1.67% and a negative net margin of 11.24%. During the same quarter in the prior year, the company posted $0.03 earnings per share. Sell-side analysts forecast that Enhabit will post 0.25 EPS for the current year.

Institutional Trading of Enhabit

A number of institutional investors have recently bought and sold shares of EHAB. SummerHaven Investment Management LLC boosted its holdings in Enhabit by 2.8% in the second quarter. SummerHaven Investment Management LLC now owns 61,508 shares of the company’s stock valued at $549,000 after purchasing an additional 1,660 shares in the last quarter. FMR LLC raised its stake in Enhabit by 138.4% during the 3rd quarter. FMR LLC now owns 3,388 shares of the company’s stock worth $27,000 after acquiring an additional 1,967 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Enhabit by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 37,950 shares of the company’s stock valued at $443,000 after acquiring an additional 2,078 shares during the last quarter. Quarry LP boosted its stake in Enhabit by 242.2% in the second quarter. Quarry LP now owns 3,703 shares of the company’s stock valued at $33,000 after acquiring an additional 2,621 shares in the last quarter. Finally, Gladius Capital Management LP grew its holdings in shares of Enhabit by 78.2% during the third quarter. Gladius Capital Management LP now owns 6,259 shares of the company’s stock worth $49,000 after purchasing an additional 2,747 shares during the last quarter.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.